Theralase Technologies Inc. V.TLT

PP not close yet.

[Lesalpes29]

Intriguing no?

[Yoly900]

Total scam total this is pathetic behavior of a pos company all dates are off they're always late or fk up on shite total idiots in this company they took our money long time ago glad I sold july fk them have squat 

[RetiredREX]

Very....

[jewel9m]

The PP not closing is not sitting well. We are 3 weeks past due on the closing of the second surprise PP. You would think that opeing up a second PP after the first closed with insider participation would have been mostly spoken for and easy to close. Just goes to show the company has a history of delays and needs to do better. To gain investor confidence they need to be better at communicating

[riverrrow]

The second pp is a bonus financing likely made available because of interest shown by smaller TLT investors.  Research Capital likely misjudged how many investors were willing to open up an account at Research Capital in order to participate.   Since this second pp is not a critical financing it really doesn;t matter how long it takes to close.  I suspect anybody willing to

[Infinity]

Seems likely Research capital misjudged the market and their clients' willingness to invest in a tightening money market..and uncertainity of the war adds to the cautious approach of their clients.

[ScienceFirst]

If there was a big pharma that finally decided to step in for jv discussions, that would produce similar delays.  We'll see if this can be that.  It's a possibility, given: - that we're 45% into a pivotal NMIBC ph. 2 - that Breakthrough application will be possible by mid-December - that we already qualify (and even surpass) surrogate points required by the Accelerated

[Infinity]

I agree. Believe the delay in closing the follow up PP is intriguing. Some thing is brewing, could be a major investor. Don't think a JV though. The $ value of the second P P is not big enough for a J V. GL T A

[ScienceFirst]

Infinity ... PP could be replaced by a jv.  Not used for a jv.  That's what I meant. We'll see.

[ScienceFirst]

By agreing to a jv for the NMIBC indication, as TLT will have to find sooner or later a big pharma that has its entries in urologist's offices if it is to be granted Accelerated Approval designation (ref. Feb. 7, 2022 presentation mentioning commercial revenues (projected) early 2023), TLT would be given upfront payment, on top of royalties, in recognition of past R&D expenses and risk

[ScienceFirst]

At this point in time, TLT just don't need money.  It needs people/contacts with connections.  People that will allow it to move to higher gears, higher levels, so it can exploit all its potential.  All businesses hat grow go through similar process.